Novartis’s Oncology Business Continues Its Strong Showing in Q1

Promacta/Revolade and Jakavi

In the first quarter, Novartis’s (NVS) Promacta/Revolade reported revenue of $307 million, a YoY (year-over-year) rise of 24% on a constant currency basis. According to the company’s first-quarter earnings press release, this performance was driven by a rapid uptake across all markets in chronic immune thrombocytopenia indications. According to the company’s first-quarter earnings investor presentation, Promacta/Revolade was launched in first-line severe aplastic anemia indications in the US market in the first quarter. The drug is supported by more than ten years of real-world data.

In the first quarter, Jakavi reported revenue of $258 million, a YoY rise of 20% on a constant currency basis. According to the company’s first-quarter earnings press release, this performance was driven by the rapid uptake in myelofibrosis and polycythemia vera indications across all markets.

Novartis’s Oncology Business Continues Its Strong Showing in Q1

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Lutathera performance

Novartis added radioligand therapy Lutathera to its portfolio through its acquisition of Advanced Accelerator Applications, which it completed on January 22, 2018. On January 26, 2018, the FDA approved Lutathera in gastroenteropancreatic neuroendocrine tumor indications.

In the first quarter, Lutathera reported revenue of $106 million. According to the company’s first-quarter earnings press release, this performance was mainly driven by the US market, in which 120 centers were actively treating patients with the therapy. According to the company’s first-quarter earnings conference call, by the end of the first quarter, the drug had been used by 2,000 patients since its launch in the US market. Lutathera’s launch in the European market is also progressing at a robust pace, with reimbursement and access already secured in the United Kingdom, Italy, and certain other markets.

In the first quarter, Novartis reported total sales of $163 million for all brands acquired from Advanced Accelerator Applications.